Naruse I, Saijo N
Pharmacology Division, National Cancer Center Research Institute.
Gan To Kagaku Ryoho. 1997 Oct;24 Suppl 3:451-9.
Lung cancer is classified into small cell lung cancer (SCLC) and non-SCLC (NSCLC) based on their clinical and biological characteristics. Chemotherapy is currently a primary treatment modality for SCLC, which is divided into two groups: limited and extensive stage. In the limited stage, radiotherapy is added to chemotherapy to improve the treatment result. In the extensive stage, only chemotherapy provides a survival benefit. In NSCLC, surgical resection is a main treatment modality in stage I, II, and some stage III patients. Other unresectable patients are treated by cisplatin-based chemotherapy and/or radiotherapy with limited benefit. Most of lung cancer patients need systemic therapy, so chemotherapy is important for its treatment. However, the agents which are commonly used for treatment of lung cancer are not sufficiently beneficial. Further improvement, including development of new anti-cancer agents, is expected.
肺癌根据其临床和生物学特征分为小细胞肺癌(SCLC)和非小细胞肺癌(NSCLC)。化疗是目前小细胞肺癌的主要治疗方式,小细胞肺癌分为两组:局限期和广泛期。在局限期,放疗联合化疗以提高治疗效果。在广泛期,仅化疗能带来生存获益。在非小细胞肺癌中,手术切除是Ⅰ期、Ⅱ期和部分Ⅲ期患者的主要治疗方式。其他无法切除的患者接受以顺铂为基础的化疗和/或放疗,获益有限。大多数肺癌患者需要全身治疗,因此化疗对其治疗很重要。然而,常用于治疗肺癌的药物获益并不充分。人们期待进一步的改进,包括开发新的抗癌药物。